Cancer
Malignant Liver Neoplasm
CI-CAN-00003177Explore in graph →
Top-level908 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003177Explore in graph →
Clinical trials
4,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (460)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00820339 | Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy(SHVE) | completed | Phase 2 / Phase 3 | 132 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00826384 | Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion | completed | Phase 1 / Phase 2 | 352 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 |
| Apr 1, 2016 |
| clinicaltrials |
| NCT00827554 | The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma | completed | Phase 2 / Phase 3 | 100 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00849264 | Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients | completed | Phase 2 | 120 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02715362 | A Study of GPC3 Redirected Autologous T Cells for Advanced HCC(GPC3-CART) | unknown | Phase 1 / Phase 2 | 30 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Mar 22, 2016 | clinicaltrials |
| NCT00877071 | LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed(HCC) | completed | Phase 2 | 2 | University of PittsburghOTHER | 1 | Mar 11, 2016 | clinicaltrials |
| NCT00987935 | A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients | completed | Phase 2 | 134 | Boehringer IngelheimINDUSTRY | 2 | Mar 10, 2016 | clinicaltrials |
| NCT01466881 | Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 2 | Mar 10, 2016 | clinicaltrials |
| NCT02702323 | Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study | unknown | Phase 2 / Phase 3 | 40 | Zhejiang Cancer HospitalOTHER | 0 | Mar 8, 2016 | clinicaltrials |
| NCT00055692 | Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Feb 29, 2016 | clinicaltrials |
| NCT02447263 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Cancer | completed | Phase 1 / Phase 2 | 87 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT02449109 | Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Carcinoma | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT00582400 | A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver | terminated | Phase 2 | 9 | The University of Texas Medical Branch, GalvestonOTHER | 1 | Feb 19, 2016 | clinicaltrials |
| NCT00532441 | Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas | terminated | Phase 2 | 25 | Gabi Chiorean, MDOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT02672488 | Metformin Plus Sorafenib for Advanced HCC | unknown | Phase 2 | 82 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 3, 2016 | clinicaltrials |
| NCT00712790 | Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 35 | Singapore Clinical Research InstituteOTHER | 4 | Jan 6, 2016 | clinicaltrials |
| NCT02632006 | Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 40 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT02632188 | Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT02638857 | Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT01715532 | Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase | unknown | Phase 2 | 120 | Fudan UniversityOTHER | 1 | Dec 18, 2015 | clinicaltrials |
| NCT02133079 | Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96 | unknown | Phase 1 / Phase 2 | 20 | Cure&Sure Biotech Co., LTDINDUSTRY | 1 | Dec 11, 2015 | clinicaltrials |
| NCT01232296 | A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment | completed | Phase 2 | 162 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 4, 2015 | clinicaltrials |
| NCT00807300 | Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma(CEAL) | completed | Phase 2 | 77 | University of MagdeburgOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT02008929 | to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)(MG4101) | completed | Phase 2 | 5 | Samsung Medical CenterOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00024258 | Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors | completed | Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2015 | clinicaltrials |
| NCT00524498 | A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma | completed | Phase 2 | 60 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 15, 2015 | clinicaltrials |
| NCT01882946 | Safety and Efficacy Study of DCVax-Direct in Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Northwest BiotherapeuticsINDUSTRY | 1 | Oct 7, 2015 | clinicaltrials |
| NCT01239355 | MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy | terminated | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 5, 2015 | clinicaltrials |
| NCT00131937 | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2015 | clinicaltrials |
| NCT00244348 | Hepatic Artery Infusion With Oxaliplatin | withdrawn | Phase 1 / Phase 2 | 0 | Medical College of WisconsinOTHER | 1 | Aug 27, 2015 | clinicaltrials |
| NCT02528526 | Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm(OXY1A) | unknown | Phase 1 / Phase 2 | 69 | University of ZurichOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT01539018 | Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE | terminated | Phase 2 | 77 | Egyptian Society of Liver CancerOTHER | 1 | Aug 5, 2015 | clinicaltrials |
| NCT02509169 | Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Shenzhen SiBiono GeneTech Co.,LtdINDUSTRY | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00365391 | Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2015 | clinicaltrials |
| NCT01009801 | Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 27 | Swiss Cancer InstituteOTHER | 1 | Jul 7, 2015 | clinicaltrials |
| NCT01030757 | Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver | terminated | Phase 2 | 2 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 7, 2015 | clinicaltrials |
| NCT01686880 | Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver(TRYPHON) | terminated | Phase 2 | 10 | Jules Bordet InstituteOTHER | 1 | Jul 1, 2015 | clinicaltrials |
| NCT01775280 | Response of Hepatic Tumors to Radioembolization(RESRAD) | withdrawn | Phase 2 | 0 | University of ZurichOTHER | 1 | Jun 9, 2015 | clinicaltrials |
| NCT01406574 | Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 23 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT02452853 | HR Combined With FOLFOX4 for HCC With PVTT | unknown | Phase 2 | 51 | Sun Yat-sen UniversityOTHER | 0 | May 25, 2015 | clinicaltrials |
| NCT00493883 | Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors | completed | Phase 1 / Phase 2 | 81 | Southwestern Regional Medical CenterOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00107536 | Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT02426450 | RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC | unknown | Phase 2 | 28 | Sun Yat-sen UniversityOTHER | 1 | Apr 27, 2015 | clinicaltrials |
| NCT02418988 | Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 120 | Shenzhen SiBiono GeneTech Co.,LtdINDUSTRY | 1 | Apr 17, 2015 | clinicaltrials |
| NCT01029418 | AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 30 | National Cancer Centre, SingaporeOTHER | 1 | Apr 16, 2015 | clinicaltrials |
| NCT00006016 | Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00081900 | A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care | terminated | Phase 1 / Phase 2 | 38 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 13, 2015 | clinicaltrials |
| NCT01003015 | Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma | completed | Phase 2 | 36 | BayerINDUSTRY | 4 | Apr 3, 2015 | clinicaltrials |
| NCT00831844 | Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 2 | 116 | National Cancer Institute (NCI)NIH | 3 | Mar 30, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Apr 1, 2016source: clinicaltrials